Race Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development

MT Newswires Live

03-05

Race Oncology (ASX:RAC) signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.

This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.

After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.

Its shares rose 3% on market close on Wednesday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517578469"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517578469\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517578469?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 13:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517578469","market":"fut","top_or_hot":-1,"title":"Race Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development","media":"MT Newswires Live","content":"<html><body><p> Race Oncology (ASX:RAC) signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.</p><p>This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.</p><p>After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.</p><p>Its shares rose 3% on market close on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Race Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Signs Nearly AU$9 Million Contract to Support Drug Candidate Development\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-03-05 13:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p> Race Oncology (ASX:RAC) signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.</p><p>This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.</p><p>After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.</p><p>Its shares rose 3% on market close on Wednesday.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"醫藥生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2517578469","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517578469","pubTimestamp":1741152914,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.Its shares rose 3% on market close on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","XJO.AU":"标普/澳交所 200指数","RAC.AU":"RACE ONCOLOGY LTD","XKO.AU":"标普/澳交所 300指数"},"translate_title":"Race Oncology签署近900万澳元合同支持候选药物开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":0.9,"XAO.AU":0.77,"XJO.AU":0.77,"XKO.AU":0.77},"content_text":"Race Oncology (ASX:RAC) signed an AU$8.6 million contract with the Contract Research Organization, George Clinical International, to support the RAC-010 Phase 1 trial of its RC220 bisantrene drug candidate in combination with doxorubicin in adult patients with advanced tumors across sites in Australia, Hong Kong, and South Korea, according to a Wednesday Australian bourse filing.This covers all outsourced trial-related services, investigator grants, and pass-through costs for up to 53 patients for the dose escalation and dose expansion stages of the trial.After an interim analysis, the optimal dosage of RC220 bisantrene in combination with doxorubicin will be evaluated in further patients for safety, tolerability, and preliminary cardioprotective and anti-cancer efficacy properties.Its shares rose 3% on market close on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}